EU regulatory authorities granted conditional approval to Regeneron’s bispecific antibody odronextamab for two forms of lymphoma.
It’s Regeneron’s first bispecific antibody approval in the world …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.